Introduction Melanoma is Australia’s fourth most common cancer. Early detection is fundamental in maximising health outcomes and minimising treatment costs. To date, population-based screening programmes have not been justified in health economic studies. However, a skin surveillance approach targeting high-risk individuals could improve the cost-benefit ratio. Methods and analysis This paper describes a 2-year longitudinal randomised controlled trial (RCT) to compare routine clinical care (control) with an intensive skin surveillance programme (intervention) consisting of novel three-dimensional (3D) total-body photography (TBP), sequential digital dermoscopy and melanoma-risk stratification, in a high-risk melanoma cohort. Primary outcomes will evaluate clinical, economic and consumer impact of the intervention. Clinical outcomes will evaluate differences in the rate of lesion excisions/biopsies per person, benign to malignant ratio for excisions and thickness of melanomas diagnosed. A health economic analysis using government data repositories will capture healthcare utilisation and costs relating to skin surveillance. Consumer questionnaires will examine intervention acceptability, the psychological impact, and attitudes towards melanoma risk and sun protective behaviour. Secondary outcomes include the development of a holistic risk algorithm incorporating clinical, phenotypic and genetic factors to facilitate the identification of those most likely to benefit from this surveillance approach. Furthermore, the feasibility of integrating the intervention with teledermatology to enhance specialist care in remote locations will be evaluated. This will be the first RCT to compare a targeted surveillance programme utilising new 3D TBP technology against current routine clinical care for individuals at high risk of melanoma. Ethics and dissemination This study has received Human Research Ethics Committee (HREC) approval from both Metro South Health HREC (HREC/17/QPAH/816) and The University of Queensland HREC (2018000074). Trial registration number ANZCTR12618000267257; Pre-results.
Terahertz (THz) imaging has long held promise for skin cancer detection but has been hampered by the lack of practical technological implementation. In this article, we introduce a technique for discriminating several skin pathologies using a coherent THz confocal system based on a THz quantum cascade laser. High resolution in vivo THz images (with diffraction limited to the order of 100 μm) of several different lesion types were acquired and compared against one another using the amplitude and phase values. Our system successfully separated pathologies using a combination of phase and amplitude information and their respective surface textures. The large scan field (50 × 40 mm) of the system allows macroscopic visualization of several skin lesions in a single frame. Utilizing THz imaging for dermatological assessment of skin lesions offers substantial additional diagnostic value for clinicians. THz images contain information complementary to the information contained in the conventional digital images.
20 January 2024 in Journal of Investigative Dermatology
Background: The surge in AI models for diagnosing skin lesions through image analysis is notable, yet their clinical implementation faces challenges. Common limitations include an over reliance on dermoscopy, lack of real‐world applicability when only binary output (e.g. benign/malignant) is offered and low accuracy when faced with rare skin conditions. Objectives: To address these common constraints associated with limited diagnostic output, and applicability to real‐world settings. Methods: We developed an All‐In‐One H ierarchical‐ O ut of Distribution‐Clinical T riage ( HOT ) AI model for skin lesion analysis. Trained on a large dataset of ~208,000 lesion images, our HOT AI model generates three outputs: a hierarchical three‐level prediction, an alert for out‐of‐distribution (OOD) images and a recommendation for dermoscopy to improve diagnostic prediction. Results: Our hierarchical prediction output provides a binary level 1 prediction (benign/malignant), Level 2 prediction of eight possible categories (e.g. melanocytic and keratinocytic) and a more definitive Level 3 prediction from 44 lesion categories. The model produced high sensitivity for Level 1 prediction (88.14% CI: 87.42–88.51); however, significantly lower for Level 3 prediction (63.90%, CI: 62.27–65.61). By relying on all three prediction levels for consensus, Level 1 false‐positives were reduced by 20–25%, and false‐negatives were decreased by 11–13% of cases. OOD detection was benchmarked against previous landmark models and outperformed comparative models. Lastly, 44% of images were recommended for dermoscopy, and with additional image input, Level 3 sensitivity increased from 48.13% (CI:45.08–49.57) to 52.54% (CI:50.25–55.04). Conclusions: Our HOT‐AI model attempts to address common challenges in existing models by combining three tasks in one model to increase accuracy and clinical utility. By providing a more nuanced prediction, and alert for OOD, the model output provides greater explainability of the AI decision process. Prospective clinical testing is required to measure how this additional output impacts user trust, and how the model performs in a real‐world setting.